About FM/a®

The FM/a® Test is performed by EpicGenetics, Inc., a privately held biomedical company based in Los Angeles, California. It was developed based upon a clinical scientific study, which was accomplished by a research team at the University of Illinois College of Medicine at Chicago which was led by Professor Frederick Behm, Department Head of the Department of Pathology. Their peer-reviewed, published manuscript is available in full at BMC Clinical Pathology.

The findings of Professor Behm’s team led the prestigious American Association for Clinical Chemistry to bestow their “Outstanding Research in Clinical Immunology” award to this group for their scientific discovery.

Subsequently, Professor Daniel Wallace of the David Geffen School of Medicine at UCLA, a world renown rheumatologist and expert in fibromyalgia, with multiple textbook publications led a research team in a nearly 500 patient study of immune system biomarkers in reference to fibromyalgia. Those results were presented by Professor Wallace at the 2013 annual conference of the American College of Rheumatology and were published in a peer-reviewed medical journal, which is available at Rheumatology International. The findings of Professor Wallace’s group re-confirmed in a second and separate laboratory the original discovery from the University of Illinois College of Medicine and they demonstrated that the fibromyalgia biomarkers that make up the FM/a® Test do not normally occur in other rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

The FM/a® Test is an immunological test system(NCBI/NLM/NIH) that has been peer-reviewed and published in leading medical journals, it was developed at the University of Illinois College of Medicine at Chicago and has been accepted for reimbursement by multiple health insurance plans.

Authorizing and Ordering FM/a®

If you’re a Nurse Practitioner, Physician’s Assistant, Chiropractor, Physician, or other licensed medical practitioner and you’d like to authorize a test on behalf of your patient, use this link to the Medical Practitioners Authorization Form. When completed, please fax the form to: 310-552-1940.

Many people with fibromyalgia have expressed concern that they may be more susceptible to a Corona virus/Covid-19 infection. We at EpicGenetics are working to determine whether or not that is true. We have begun polling those who have had their diagnosis of fibromyalgia confirmed via the FM/a® Test as to whether they have been diagnosed with a Covid-19 infection and/or they have the symptoms of such an infection, including fevers, coughing, tiredness and respiratory distress.

It is true that patients with fibromyalgia have some indications of immune system deficiencies, per our peer-reviewed and published research. Therefore, we ask anyone with a positive FM/a® Test score to 1) take precautions and isolate themselves, per the WHO and CDC guidelines, and 2) notify us at EpicGenetics if they develop and/or are diagnosed with a Covid-19 infection. That information will help us determine any potential increased risks for fibromyalgia patients regarding the Covid-19 virus.

Please protect yourself, your families and your friends. This is a very serious medical pandemic. Be assured that we at EpicGenetics want to help and are working hard to do so any way that we can.